These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 34735919

  • 1. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
    Craig SN, Baxter M, Chapagai D, Stafford JM, Nurmemmedov E, Altomare D, Wyatt MD, McInnes C.
    Eur J Med Chem; 2022 Jan 05; 227():113926. PubMed ID: 34735919
    [Abstract] [Full Text] [Related]

  • 2. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
    Chapagai D, Ramamoorthy G, Varghese J, Nurmemmedov E, McInnes C, Wyatt MD.
    J Med Chem; 2021 Jul 22; 64(14):9916-9925. PubMed ID: 34210138
    [Abstract] [Full Text] [Related]

  • 3. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells.
    Li P, Li Y, Ma X, Li L, Zeng S, Peng Y, Liang H, Zhang G.
    Eur J Med Chem; 2024 May 05; 271():116416. PubMed ID: 38657480
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
    Chen Y, Zhang J, Li D, Jiang J, Wang Y, Si S.
    Oncotarget; 2017 Jan 03; 8(1):1234-1246. PubMed ID: 27902479
    [Abstract] [Full Text] [Related]

  • 10. Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1.
    Richter S, Neundorf I, Loebner K, Gräber M, Berg T, Bergmann R, Steinbach J, Pietzsch J, Wuest F.
    Bioorg Med Chem Lett; 2011 Aug 15; 21(16):4686-9. PubMed ID: 21778054
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
    Chen DX, Huang J, Liu M, Xu YG, Jiang C.
    Arch Pharm (Weinheim); 2015 Jan 15; 348(1):2-9. PubMed ID: 25430493
    [Abstract] [Full Text] [Related]

  • 13. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
    Lv X, Yang X, Zhan MM, Cao P, Zheng S, Peng R, Han J, Xie Z, Tu Z, Liao C.
    Eur J Med Chem; 2019 Dec 15; 184():111769. PubMed ID: 31629162
    [Abstract] [Full Text] [Related]

  • 14. Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.
    Murugan RN, Park JE, Kim EH, Shin SY, Cheong C, Lee KS, Bang JK.
    Mol Cells; 2011 Sep 15; 32(3):209-20. PubMed ID: 21809214
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
    Park JE, Kim TS, Kim BY, Lee KS.
    Cell Cycle; 2015 Sep 15; 14(22):3624-34. PubMed ID: 26513691
    [Abstract] [Full Text] [Related]

  • 19. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
    Pezuk JA, Brassesco MS, Ramos PMM, Scrideli CA, Tone LG.
    Anticancer Agents Med Chem; 2017 Sep 15; 17(9):1278-1291. PubMed ID: 28270075
    [Abstract] [Full Text] [Related]

  • 20. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
    Pan Z, Chen Y, Liu J, Jiang Q, Yang S, Guo L, He G.
    Eur J Med Chem; 2018 Jan 20; 144():517-528. PubMed ID: 29288948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.